# A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

> **NCT03463876** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 190 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** SHR 1210+apatinib

## Key facts

- **NCT ID:** NCT03463876
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-08
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-10
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03463876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03463876, "A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03463876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*